Stockhead on MSN10h
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
Imugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells.